$701 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 131 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | GILEAD SCIENCES INC | $18,635,000 | +14.5% | 230,000 | 0.0% | 2.66% | -3.9% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $18,270,000 | -5.8% | 450,000 | 0.0% | 2.61% | -20.9% | |
| PFE | PFIZER INC | $13,923,000 | +6.3% | 390,000 | 0.0% | 1.99% | -10.8% | |
| V | VISA INC | $5,573,000 | +12.2% | 52,951 | 0.0% | 0.80% | -5.8% | |
| FB | FACEBOOK INCcl a | $5,496,000 | +13.2% | 32,167 | 0.0% | 0.78% | -5.0% | |
| SVRA | SAVARA INC | $4,921,000 | +59.0% | 526,315 | 0.0% | 0.70% | +33.5% | |
| CHTR | CHARTER COMMUNICATIONS INC Ncl a | $4,856,000 | +7.9% | 13,362 | 0.0% | 0.69% | -9.4% | |
| SELB | SELECTA BIOSCIENCES INC | $4,171,000 | -8.1% | 228,534 | 0.0% | 0.60% | -22.8% | |
| STML | STEMLINE THERAPEUTICS INC | $3,330,000 | +20.7% | 300,000 | 0.0% | 0.48% | +1.3% | |
| CASC | CASCADIAN THERAPEUTICS INC | $2,786,000 | +10.1% | 681,210 | 0.0% | 0.40% | -7.7% | |
| AXSM | AXSOME THERAPEUTICS INC | $2,781,000 | +0.9% | 501,000 | 0.0% | 0.40% | -15.2% | |
| OVID | OVID THERAPEUTICS INC | $2,620,000 | -13.9% | 305,674 | 0.0% | 0.37% | -27.7% | |
| CLSD | CLEARSIDE BIOMEDICAL INC | $2,622,000 | -4.1% | 300,000 | 0.0% | 0.37% | -19.4% | |
| ORCL | ORACLE CORP | $2,285,000 | -3.5% | 47,250 | 0.0% | 0.33% | -18.9% | |
| ARDX | ARDELYX INC | $1,932,000 | +9.8% | 345,000 | 0.0% | 0.28% | -7.7% | |
| VTVT | VTV THERAPEUTICS INCcl a | $1,794,000 | +20.3% | 300,000 | 0.0% | 0.26% | +1.2% | |
| ALRN | AILERON THERAPEUTICS INC | $1,673,000 | +20.0% | 125,000 | 0.0% | 0.24% | +0.8% | |
| MA | MASTERCARD INCORPORATEDcl a | $1,627,000 | +16.2% | 11,525 | 0.0% | 0.23% | -2.5% | |
| VRSK | VERISK ANALYTICS INC | $782,000 | -1.4% | 9,400 | 0.0% | 0.11% | -17.0% | |
| GNCA | GENOCEA BIOSCIENCES INC | $715,000 | -72.0% | 490,000 | 0.0% | 0.10% | -76.6% | |
| ITEK | INOTEK PHARMACEUTICALS CORP | $715,000 | -6.3% | 401,764 | 0.0% | 0.10% | -21.5% | |
| XENE | XENON PHARMACEUTICALS INC | $673,000 | -6.3% | 228,029 | 0.0% | 0.10% | -21.3% | |
| CATB | CATABASIS PHARMACEUTICALS IN | $611,000 | +49.4% | 288,030 | 0.0% | 0.09% | +26.1% | |
| UNH | UNITEDHEALTH GROUP INC | $392,000 | +5.7% | 2,000 | 0.0% | 0.06% | -11.1% | |
| WSO | WATSCO INC | $338,000 | +4.3% | 2,100 | 0.0% | 0.05% | -12.7% | |
| MHK | MOHAWK INDS INC | $272,000 | +2.3% | 1,100 | 0.0% | 0.04% | -13.3% | |
| LOW | LOWES COS INC | $208,000 | +3.0% | 2,600 | 0.0% | 0.03% | -11.8% | |
| SEE | SEALED AIR CORP NEW | $192,000 | -4.5% | 4,500 | 0.0% | 0.03% | -20.6% | |
| LVNTA | LIBERTY INTERACTIVE CORP | $173,000 | +10.2% | 3,000 | 0.0% | 0.02% | -7.4% | |
| TRIP | TRIPADVISOR INC | $162,000 | +5.9% | 4,000 | 0.0% | 0.02% | -11.5% | |
| ULTI | ULTIMATE SOFTWARE GROUP INC | $152,000 | -9.5% | 800 | 0.0% | 0.02% | -24.1% | |
| XRAY | DENTSPLY SIRONA INC | $150,000 | -7.4% | 2,500 | 0.0% | 0.02% | -25.0% | |
| VSTO | VISTA OUTDOOR INC | $138,000 | +2.2% | 6,000 | 0.0% | 0.02% | -13.0% | |
| CMG | CHIPOTLE MEXICAN GRILL INC | $123,000 | -25.9% | 400 | 0.0% | 0.02% | -35.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2017-11-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.